DUBLIN, July 10, 2018 /PRNewswire/ -- Allergan plc
(NYSE: AGN), a leading global pharmaceutical company, today
announced the launch of a new over-the-counter (OTC) artificial
tear formulation, REFRESH® REPAIR Lubricant Eye Drops.
The first and only artificial tear in the U.S. formulated with
carboxymethylcellulose (CMC), hyaluronic acid (HA, an inactive
ingredient), and osmoprotectants, REFRESH® REPAIR is the
latest addition to the REFRESH® portfolio, the number
one doctor-recommended brand of artificial tears.
REFRESH® REPAIR tears are designed to repair and protect
the eyes from the harmful effects of dry eye and improve clarity of
vision.
"Our new REFRESH® artificial tear,
REFRESH® REPAIR, offers eye doctors an additional option
to tailor therapy to the specific needs of their patients.
REFRESH® REPAIR provides improved comfort for patients
with dry eye and unique osmoprotective benefits that safeguard the
health of epithelial cells against hyperosmotic stress," said Jag
Dosanjh, Senior Vice President, Allergan US Eye Care.
Over 33 million people in the United States suffer
from dry eye symptoms, including irritation, blurred vision,
sensitivity to light, burning, stinging, dryness and excessive
tearing. Dry eye is often a chronic disease that can be caused
by advanced age, contact lens wear, certain medications, eye
diseases, other medical conditions or environmental factors.
Without enough tears, the film protecting the eye can break down,
creating dry spots on the cornea. In clinical studies,
REFRESH® REPAIR was shown to improve signs and symptoms
of dry eye and improve visual performance in dry eye patients, with
low incidence of side effects such as blur and stickiness during
blinking.
"As dry eye science has gotten more sophisticated over the past
decade, we have come to appreciate the conditions necessary for a
healthy ocular surface, which REFRESH® REPAIR is
designed to support," said Marc
Bloomenstein, OD. "With REFRESH® REPAIR, I can
recommend a brand I trust, knowing that my patients will get the
benefit of a formulation that helps promote healing of ocular
surface cells so the ocular surface can function properly."
About REFRESH® REPAIR
REFRESH® REPAIR Lubricant Eye Drops are clinically
proven to treat the signs and symptoms of dry eye and improve
visual performance due to dry eye, while offering patients improved
comfort with low incidence of visual disturbances.
REFRESH® REPAIR is the only artificial tear brand
formulated with carboxymethylcellulose (CMC), hyaluronic acid
(HA, an inactive ingredient), and osmoprotectants. These
restorative osmoprotectants displace salt in the tear film to
safeguard epithelial cells against hyperosmotic stress, thus
helping maintain the health of the ocular surface.
REFRESH® REPAIR is safe to use with contact lenses.
REFRESH® REPAIR Lubricant Eye Drops expand the options
within the trusted REFRESH® line of artificial
tears.
Learn more about REFRESH® REPAIR
at www.refreshbrand.com.
Allergan: 70 Years Advancing Eye Care
As a leader in eye care, Allergan has discovered,
developed, and delivered some of the most innovative products in
the industry over the last 70 years. Allergan has launched
over 125 eye care products and invested billions of dollars in new
treatments for the most prevalent eye conditions including
glaucoma, ocular surface disease, and retinal diseases such as
diabetic macular edema and retinal vein occlusion. Our eye care
pipeline includes 13 additional agents for multiple ocular
conditions.
Our commitment to the well-being of patients is also reflected
in philanthropy. Allergan and The Allergan
Foundation support more than 150 organizations around the
world working to improve lives and communities. We remain
steadfast in helping eye care providers deliver the best in patient
care through innovative products and outreach programs.
About Allergan plc
Allergan plc (NYSE: AGN), headquartered in Dublin, Ireland, is a bold, global
pharmaceutical leader. Allergan is focused on developing,
manufacturing and commercializing branded pharmaceutical, device,
biologic, surgical and regenerative medicine products for patients
around the world.
Allergan markets a portfolio of leading brands and best-in-class
products for the central nervous system, eye care, medical
aesthetics and dermatology, gastroenterology, women's health,
urology and anti-infective therapeutic categories.
Allergan is an industry leader in Open Science, a model of
research and development, which defines our approach to identifying
and developing game-changing ideas and innovation for better
patient care. With this approach, Allergan has built one of the
broadest development pipelines in the pharmaceutical industry.
Allergan's success is powered by our global colleagues'
commitment to being Bold for Life. Together, we build bridges,
power ideas, act fast and drive results for our customers and
patients around the world by always doing what is right.
With commercial operations in approximately 100 countries,
Allergan is committed to working with physicians, healthcare
providers and patients to deliver innovative and meaningful
treatments that help people around the world live longer, healthier
lives every day.
For more information, visit Allergan's website
at www.Allergan.com.
Forward-Looking Statement
Statements contained in this press release that refer to future
events or other non-historical facts are forward-looking statements
that reflect Allergan's current perspective on existing trends and
information as of the date of this release. Actual results may
differ materially from Allergan's current expectations depending
upon a number of factors affecting Allergan's business. These
factors include, among others, the difficulty of predicting the
timing or outcome of FDA approvals or actions, if any; the impact
of competitive products and pricing; market acceptance of and
continued demand for Allergan's products; the impact of uncertainty
around timing of generic entry related to key products, including
RESTASIS®, on our financial results; risks associated
with divestitures, acquisitions, mergers and joint ventures;
uncertainty associated with financial projections, projected cost
reductions, projected synergies, restructurings, increased costs,
and adverse tax consequences; difficulties or delays in
manufacturing; and other risks and uncertainties detailed in
Allergan's periodic public filings with the Securities and Exchange
Commission, including but not limited to Allergan's Annual Report
on Form 10-K for the year ended December 31,
2017 and Allergan's Quarterly Report on Form 10-Q for the
period ended March 31, 2018. Except
as expressly required by law, Allergan disclaims any intent or
obligation to update these forward-looking statements.
CONTACTS:
|
Allergan:
|
|
Investors:
|
|
Daphne
Karydas
|
|
(862)
261-8006
|
|
|
|
Media:
|
|
Amy Rose
|
|
(862)
261-7001
|
|
|
|
Lisa Kim
|
|
(714)
246-3843
|
View original content with
multimedia:http://www.prnewswire.com/news-releases/allergan-expands-refresh-portfolio-with-new-refresh-repair-lubricant-eye-drops-300677992.html
SOURCE Allergan plc